“…[17] The protective effects of CAPE have been practiced in various studies dealing with cerebral ischemia-reperfusion injury, spinal cord ischemia-reperfusion injury, Parkinson's disease, hypoxic ischemic brain damage in newborns, multiple sclerosis, convulsions, brain tumors, toxic effects of therapeutic agent in anticancer therapies, and hepatic encephalopathy. [3][4][5][6][7][8][9][10][11] There are only five studies in the literature evaluating the effects of CAPE in the spinal cord. [5,8,11,18,19] Two of these studies have been performed to evaluate the protective effects of CAPE against experimental allergic encephalomyelitisinduced oxidative stress, and in methotrexate administered rats.…”